Publications

Lagiakos HR, Zou Y, Igawa H, Therrien E, Lawrenz M, Kato M, Svensson M, Gray F, Jensen K, Dahlgren M, Pelletier R, Dingley K, et al. 2025. In silico enabled discovery of KAI-11101, a preclinical DLK inhibitor for the treatment of neurodegenerative disease and neuronal injury. J Med Chem 68(3):2720-2741; doi: 10.1021/acs.jmedchem.4c02074. PMID: 39670820.

Xue Y, Wang L, Huo R, Chen M, Melo B, Dingley K, et al. 2024. 1β-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of CYP3A clinical drug-drug interaction potential. Drug Metab Dispos 52(9):966–974; doi: 10.1124/dmd.124.001680. PMID: 38991779.

Burnett J, Sychterz C, Zhu D, Shakeel F, Dingley K, Chen W, et al. Prospective application of physiologically based pharmacokinetic (PBPK) modeling to inform the design of a clinical drug-drug interaction (DDI) study: Case study of mezigdomide. Poster presented at American Society of Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, Colorado Springs, CO, March 2024.

Lawrenz M, Svensson M, Kato M, Dingley K, et al. 2023. A computational physics-based approach to predict unbound brain-to-plasma partition coefficient, Kp,uu. Chem Inf Model 63(12):3786–3798; doi: 10.121/acs.jcim.3c00150. PMID: 37267072.

Tsvetkov L, Pittsenbarger J, Atsriku C, Devine P, Dingley K, et al. 2022. Inhibition of CDC7 with Sgr-2921 in AML models results in enhanced DNA damage and anti-leukemic activity as monotherapy and in combination with standard of care agents. Blood 140 (Supplement 1):5961–5962; doi: 10.1182/blood-2022-167239.

Yin W, Nie Z, Dingley K, Trzoss M, Krilov G, Marshall N et al. 2021. Characterization of potent paracaspase MALT1 inhibitors for hematological malignancies. Blood 138 (Supplement 1):1187; doi: 10.1182/blood-2021-153159.

Ramírez-Valle F, Adams M, Beebe L, Chen J, Chuaqui C, Connarn JN, Corin AF, Dingley KH, et al. 2019. A novel MK2 inhibitor for the treatment of ankylosing spondylitis and other inflammatory diseases. Abstract 1536, Annual Meeting of the American College of Rheumatology Conference, Atlanta, GA, November 2019.

Powles MA, Galgoci A, Misura A, Colwell L, Dingley K, Tang W, et al. 2018. In vivo efficacy of relebactam (MK-7655) in combination with imipenem/cilastatin in murine infection models. Antimicrob Agents Chemother 62:e02577–17; doi: 10.1128/AAC.02577-17. PMID: 29866878.

Liu W, Hussain Z, Zang Y, Sweis RF, Romero FA, Finke PE, … Dingley KH, et al. 2018. Optimization of preclinical metabolism for somatostatin receptor subtype 5-selective antagonists. ACS Med Chem Lett (9):1088–1093; doi: 10.1021/acsmedchemlett.8b00306. PMID: 30429950.

Wang Y, Villalta PW, Peng L, Dingley KH, Malfatti MA, Turteltaub KW, Turesky RJ. 2017. Mass spectrometric characterization of an acid-labile adduct formed with 2-amino-1-methyl-phenylimidazo[4,5-b]pyridine and albumin in humans. Chem Res Toxicol 30(2):705–714; doi: 10.1021/acs.chemrestox.6b00426. PMID: 27984695.

Harper BH, Wang L, Zhu C, Kar NF, Li B, Moyes CR, … Dingley K, et al. 2017. Investigation of piperazine benzamides as human β3 adrenergic receptor agonists for the treatment of overactive bladder. Bioorg Med Chem Lett 27(4):1094–1098; doi: 10.1016/j.bmcl.2016.12.033. PMID: 28089699.

Zhu C, Wang L, Zhu Y, Guo ZZ, Liu P, Hu Z, … Dingley KH, et al. 2017. Discovery of phenyl acetamides as potent and selective GPR119 agonists. Bioorg Med Chem Lett 27(5):1124–1128; doi: 10.1016/j.bmcl.2017.01.091. PMID: 28185720.

Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, et al. 2016. Discovery of vibegron: A potent and selective beta 3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem 59(2):609–623; doi: 10.1021/acs.jmedchem.5b01372. PMID: 26709102.

Zhu C, Kar NF, Li B, Costa M, Dingley KH, Di Salvo J, et al. 2016. Discovery of benzamides as potent human β3 adrenergic receptor agonists. Bioorg Med Chem Lett 26(1):55–59; doi: 10.1016/j.bmcl.2015.11.030. PMID: 26590100.

Wilson JE, Kurukulasuriya R, Sinz C, Matthew Lombardo, Kate Bender, Dann Parker, … Dingley K, et al. 2016. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes. Bioorg Med Chem Lett 26(12):2947–2951; doi: 10.1016/j.bmcl.2016.04.018. PMID: 27240550.

Guo L, Parker DL, Zang Y, Sweis RF, Liu W, Sherer EC, … Dingley KH, et al. 2016. Discovery and optimization of a novel triazole series of GPR142 agonists for the treatment of type 2 diabetes. ACS Med Chem Lett 7 (12):1107–1111; doi: 10.1021/acsmedchemlett.6b00314. PMID: 27994747.

Liu P, Hu Z, DuBois BG, Moyes CR, Hunter DN, Zhu C, … Dingley KH, et al. 2015. Design of potent and orally active GPR119 agonists for the treatment of type II diabetes. ACS Med Chem Lett 6(8):936–941; doi: 10.1021/acsmedchemlett.5b00207. PMID: 26288697.

Dingley KH, Ubick EA, Vogel JS, Ognibene TJ, Malfatti MA, Kulp K, Haack KW. 2014. DNA isolation and sample preparation for quantification of adduct levels by accelerator mass spectrometry. Methods Mol Biol 1105:147–157; doi: 10.1007/978-1-62703-739-6_12. PMID: 24623226.

Moyes CR, Berger R, Goble SD, Harper B, Shen DM, Wang L, … Dingley KH, et al. 2014. Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder. J Med Chem 57(4):1437–1453; doi: 10.1021/jm4017224. PMID: 24437735.

Degregorio MW, Dingley KH, Wurz GT, Ubick E, Turteltaub KW. 2006. Accelerator mass spectrometry allows for cellular quantification of doxorubicin at femtomolar concentrations. Cancer Chemother Pharmacol 57(3):335-342; doi: 10.1007/s00280-005-0060-1. PMID: 16047147.